Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | AKT2 | P31751 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631009 | 0.81 | AKT1 (0.33) | AKT1AKT2 | |
| SCHEMBL19578086 | 0.81 | NPC1 (0.39) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL25310605 | 0.80 | NPC1 (0.37) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL3027232 | 0.79 | NPC1 (0.37) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL23630957 | 0.79 | AKT1 (0.32) | AKT1AKT2 | |
| SCHEMBL28497783 | 0.78 | AKT1 (0.30) | AKT1AKT2 | |
| SCHEMBL25311795 | 0.76 | NPC1 (0.38) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL16265142 | 0.76 | NPC1 (0.35) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL19554501 | 0.73 | NPC1 (0.43) | NPC1RAB9AHPGDSMN1; SMN2TP53 | |
| SCHEMBL14126501 | 0.72 | AKT1 (0.52) | NPC1RAB9AHPGDSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021146424-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20210214366-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-07-15 | — | — | US | disclosed |
| EP-2822559-B1 | IMIDAZO[1,2-B]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | LEXICON PHARMACEUTICALS INC (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-2822559-B1 | IMIDAZO[1,2-B]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | LEXICON PHARMACEUTICALS INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| EP-2714692-B1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-20170057964-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057964-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-03-02 | — | — | US | disclosed |
| US-20110281863-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281863-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008058126-A2 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281863-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | NPC1 3669/4885RAB9A 2635/4885HPGD 2783/4885 |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | NPC1 3687/4885RAB9A 2906/4885HPGD 2537/4885 |
| US-20210214366-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR2, FGFR1 | NPC1 3755/4885RAB9A 2904/4885HPGD 959/4885 |
| US-20170057964-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | NPC1 1854/4885RAB9A 1711/4885HPGD 4028/4885 |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | NPC1 3687/4885RAB9A 2906/4885HPGD 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.